A phase 1, first-in-child, multicenter study to evaluate the safety and efficacy of the oncolytic herpes virus talimogene laherparepvec in pediatric patients with advanced solid tumors Article

Moreno, Lucas, Teira, Pierre, Croop, James M et al. (2023). A phase 1, first-in-child, multicenter study to evaluate the safety and efficacy of the oncolytic herpes virus talimogene laherparepvec in pediatric patients with advanced solid tumors . 11 10.3389/fped.2023.1183295

Open Access Industry Collaboration International Collaboration

cited authors

  • Moreno, Lucas; Teira, Pierre; Croop, James M; Gerber, Nicolas U; Andre, Nicolas; Aerts, Isabelle; Subias, Luis Gros; De Wilde, Bram; Bautista, Francisco; Turpin, Brian; Kunduri, Srinivasa; Hamidi, Ali; Lawrence, Tatiana; Streby, Keri A

sustainable development goals

authors

publication date

  • May 24, 2023

keywords

  • ADOLESCENTS
  • CHILDREN
  • COMBINATION
  • EUROPE
  • I TRIAL
  • IPILIMUMAB
  • Life Sciences & Biomedicine
  • Pediatrics
  • SIMPLEX-VIRUS
  • SURVIVAL
  • Science & Technology
  • VEC
  • immunotherapy
  • non-CNS tumors
  • oncolytic herpes virus
  • pediatric solid tumor
  • relapsed and refractory cancer
  • talimogene laherparepvec

Digital Object Identifier (DOI)

publisher

  • FRONTIERS MEDIA SA

volume

  • 11